Conclusions
SSHL
SECONDARY
Ancrod reduced fibrinogen levels supporting its mechanism of action. The safety profile can be rated positive. The planned number of patients could not be enrolled; therefore, no efficacy conclusion can be drawn. A distinct improvement of SSHL occurred in both study arms. The high placebo response rate in SSHL challenges clinical trials and needs to be considered in future investigations. Conclusions about in- and exclusion criteria, high complexity of the study protocol and logistics, and involvement of primary and secondary care providers may provide benefit for future studies.